Eli Lilly will submit orforglipron to be part of FDA’s new national priority voucher program, according to a new report. 1 ...

PE: What policy incentives are created by FDA's ANDA Prioritization Pilot? Botha: Right now, we’re seeing multiple efforts ...

The GCC is becoming a strategic anchor for global venture capital, with Riyadh emerging as a key fundraising hub. Sovereign ...

HHS Secretary Kennedy stated there is insufficient evidence to link Tylenol to autism, conflicting with the Texas lawsuit.

In today’s Pharmaceutical Executive Daily, we cover Thermo Fisher’s $8 billion agreement to acquire Clario Holdings, Eli ...

Novartis will acquire Avidity Biosciences in a newly announced definitive merger agreement. The news follows the separation ...

PE: What impact will FDA's ANDA Prioritization Pilot have on efficiency and competitiveness? Botha: Setting up new ...

CSL delayed the CSL Seqirus spin-off due to lower-than-expected US vaccination rates, affecting revenue growth and share ...

Novo Nordisk recently confirmed reports about its unsolicited proposal submission to Metsera, aimed at acquiring its early ...

The US Health Resources and Services Administration (HRSA) revealed the initial nine drugs to be included in the 340B rebate model. The decision comes after pharma companies filed suit in regard to ...

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s unsolicited proposal to acquire Metsera, renewed legal action against Tylenol’s manufacturer following statements from Robert F.